Risk of myocardial infarction with oral direct thrombin inhibitors: Trial sequential analysis based on two published data sets

American Journal of Cardiology

Volumn 113, Issue 4, 2014, Pages 746-748

  Messori, Andrea ^a   Fadda, Valeria ^a   Maratea, Dario ^a   Trippoli, Sabrina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN INHIBITOR; WARFARIN;

ALGORITHM; ANTICOAGULANT THERAPY; CORONARY RISK; HEART INFARCTION; HUMAN; HYPOTHESIS; META ANALYSIS (TOPIC); NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MYOCARDIAL INFARCTION;

EID: 84893480667     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.11.022     Document Type: Letter

References (5)

1. R. Artang, E. Rome, J.D. Nielsen, and H.J. Vidaillet Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors Am J Cardiol 112 2013 1973 1979
2. J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis J Clin Epidemiol 61 2008 64 75
3. A. Messori, V. Fadda, D. Maratea, and S. Trippoli Erythropoiesis- stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness? Eur J Heart Fail 15 2013 944 945
4. A. Messori, V. Fadda, D. Maratea, and S. Trippoli Omega-3 polyunsaturated fatty acids for patients at risk of sudden cardiac death and ventricular arrhythmias: trial sequential analysis Heart Lung 42 2013 391 392
5. A. Messori, V. Fadda, D. Maratea, and S. Trippoli ω-3 fatty acid supplements for secondary prevention of cardiovascular disease: from "no proof of effectiveness" to "proof of no effectiveness" JAMA Intern Med 173 2013 1466 1468